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ABSTRACT 
Molecular Basis of Cell Migration Inhibition by the Dietary Phytochemical Piperine 
By Henry George Annan 
 Metastasis, the migration of cells from a primary tumour site to distant tissues, is 
associated with the degradation of the epithelial basement membrane and extracellular 
matrix in connective tissue and often leads to poor prognosis in breast cancer. Matrix 
metalloproteinases (MMPs) are enzymes that are implicated in the destruction of the 
extracellular matrix and are overexpressed in breast cancer cells. Naturally occurring 
plant compounds known as phytochemicals are being investigated as possible anti-cancer 
agents. Piperine, a major alkaloid component of black pepper, is one such phytochemical 
that has shown chemotherapeutic effects in early experiments on human and mouse 
tumour cells. The current study investigates the potential of piperine to prevent cancer 
metastasis. The overall effect of piperine on MB-MDA-231 breast cancer cell migration 
was examined using a cell migration (wound-healing) assay. A mechanism of drug action 
was then explored by determining the effect of piperine on the mRNA transcription, 
production and activation of the gelatinases, MMP-2 and MMP-9, as well as the 
stromelysin, MMP-3. The cell migration assay showed that piperine significantly 
inhibited cancer cell migration at concentrations of 50 µM. RT-qPCR analysis also 
showed that piperine significantly inhibited MMP-2 and MMP-9 mRNA expression after 
48 hours of treatment. Preliminary results from western blot and gelatin zymography 
analyses indicated that piperine may also inhibit the translation and activity of MMP-2 
and MMP-9. Piperine did not appear to affect MMP-3. These results offer further insight 
into the anti-metastatic action of piperine and suggest a possible novel treatment for 
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CHAPTER 1  
INTRODUCTION 
1.1 Breast Cancer  
 Breast cancer continues to be one of the leading causes of cancer-related death in 
women across the globe, particularly in developed countries including Canada (Jemal, et 
al. 2011). A 2013 study conducted by the Public Health Agency of Canada, Statistics 
Canada and the Canadian Cancer Society, estimates that 26.1% of all new cancer cases 
affecting women will be breast cancer cases (Canadian Cancer Society's Advisory 
Committee on Cancer Statistics 2013). Meanwhile, by the same study, breast cancer 
represents only 0.2% of cancer cases in men. The report also stated that in women, 13.9% 
of those affected with breast cancer succumb to the disease, making it the second leading 
cause of cancer death among Canadian women. Although treatment options have 
improved over the past decade, there remain significant limitations when treating more 
aggressive forms of breast cancer (Al-Hajj, et al. 2003). Moreover, these treatments are 
often expensive and inaccessible in low-income settings (Bines and Eniu 2008). 
 Hormonal therapy and chemotherapy are two forms of breast cancer treatment. 
They comprise of the use of compounds that stop or slow down the progression of cancer. 
Unfortunately, hormonal therapy is infective in many breast cancer patients (Hayashi and 
Yamaguchi 2008). Furthermore, patients that undergo chemotherapy often suffer extreme 
side effects. These include anaemia, changes in appetite, irregular bowel movements, 
fatigue, nausea and vomiting (Lenz 2012). The surgical excision of a tumour is another 
option for treating breast cancer. However, studies are showing that this form of treatment 
may be associated with the potential of an accelerated relapse as a result of the release 
tumour-promoting proteins during the procedure (Pagani, et al. 2010). Finally, breast 
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cancer patients may be exposed to high levels of radiation by undergoing radiotherapy. 
Radiotherapy also has adverse side effects with almost 50% of patients experiencing 
acute encephalopathy and other nervous system disorders (Soussain, et al. 2009). The 
development of safe, effective and inexpensive anti-cancer drugs is therefore needed to 
reduce mortality and increase the quality of life in breast-cancer patients. 
1.2 Breast Cancer Metastasis 
Perhaps the single most significant contributing factor to poor prognosis in 
patients is the migration of cells from the primary tumour to a distant tissue 
(Stasinopoulos, et al. 2010). This process is known as metastasis (Ramaswamy, et al. 
2003). According to Nguyen and Massagué (2007), about 90% of deaths from solid 
tumours are a direct result of metastasis. Tumour cells from different cancers have 
preferences for metastasis to particular organs (Nicolson 1993). Breast cancer tumours 
often form secondary sites in osseous, lung and hepatic tissues (Weigelt, Peterse and van't 
Veer 2005). Preferences for breast cancer cells to these tissues are primarily due to 
chemokine signalling (Müller, et al. 2001). Although metastasis is a highly complex, 
multi-event process, many of the key steps involved have been described and are 
collectively called the metastatic cascade. They include stages of invasion, 
vascularization and the modification of normal cell adhesion and motility properties 
(Stasinopoulos, et al. 2010).  
At least three of the steps included in the metastatic cascade require some 
degradation of extracellular matrix (ECM) in order to facilitate cell migration (See Figure 
1.1). The ECM is composed of a network of proteins secreted by mesenchymal cells and 
holds epithelial tissue in place in the organ system (Alberts, et al. 2002). For this reason, 
the destruction of ECM is particularly relevant in cancers of epithelial origin, termed 
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carcinomas, of which breast cancer is an example (Kramárová and Stiller 1996). 
Epithelial cells, by definition, are anchored to a basement membrane, preventing 
locomotion. They also lack an extensive network of vessels and their main function is to 
provide protection to the underlying tissues (Alberts, et al. 2002). Depending on the type 
and tumour location, cancer cell metastasis involves of one or more of several modes. 
First, cancer cells must detach themselves from the basement membrane in order to 
become free to move into the circulatory system. This entry of cells into the circulation is 
known as intravasation. ECM surrounding the epithelium must also be degraded to allow 
the restricted cells to migrate. Finally, cancer cells leave the circulation to colonize distant 
tissues by penetrating blood or lymphatic vessels, a process known as extravasation 
(Deryugina and Quigley 2006). The degradation of ECM to facilitate cancer metastasis is 
thus an important characteristic of malignancy in carcinomas, including breast cancer. 
The development of new blood vessels from established vasculature, known as 
angiogenesis, is also a significant contributing factor to cancer cell malignancy. In fact, 
angiogenesis is often described as the rate-limiting step in tumour growth because 
tumours cannot grow beyond a certain critical size without the necessary supply of 
oxygen and nutrients by blood vessels (Zetter 1998). While angiogenesis occurs in 
normal physiological situations such as wound-healing, it is the hypoxic conditions and 
growth factor milieu in the tumour microenvironment that initiate the transcription of pro-
angiogenic factors, including angiopoietin-2 (Ang-2) and fibroblast growth factor-2 
(FGF-2) (Carmeliet and Jain, 2000). Vascular endothelial growth factor-A (VEGF-A) 
however, is the predominant inducer of angiogenesis (Carmeliet and Jain 2011). Research 
has demonstrated that the interaction between VEGF-A and its receptor tyrosine kinase, 
VEGF receptor-2 (VEGFR-2,) is primarily responsible for angiogenesis associated with 
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tumours. VEGFR-2 is one of three related receptor tyrosine kinases, the other two being 
VEGFR-1 and VEGFR-3 (Clauss 2000). There is growing evidence to suggest that 
VEGFR-1 exhibits some pro-angiogenic properties in cancer cells by recruiting 
monocytes and other cells that increase tumour vasculature (Ferrara and Kerbel 2005). In 
normal cells, signalling to stimulate the formation of blood vessels is highly regulated 
with the three VEGF receptors being implicated on multiple levels in the pathway 
(Hanahan and Weinberg 2011). Mechanisms for controlling angiogenesis are largely 
unregulated in tumour cells and, as a result, tumours are characterized by irregularly 
shaped blood vessels that are leaky with disrupted blood-flow (Baluk, Hashizume and 
McDonald 2005). Perhaps not surprisingly, in order for angiogenesis to occur, the ECM 
must be remodelled to allow for the migration of the endothelial cells that will form the 
new vasculature (Cheresh and Stupack 2008).  
 Cancer cells also differ immensely in their adhesion properties in comparison to 
healthy cells. One characteristic of epithelial cells is that that they possess adhesion 
molecules that enable them to form adherens junctions with one another and also attach to 
components of the ECM. Cell-cell adherens junctions such as these restrict the migratory 
ability of cells and regulate their proliferation (Conacci-Sorrell, Zhurinsky and Ben-Ze'ev 
2002). The disruption of normal adhesion in cancer cells is exemplified in the 
downregulation of E-cadherin in many carcinomas. E-cadherin is a transmembrane 
glycoprotein that is involved in the formation of adherens junctions between epithelial 
cells by interacting with catenin and actin components of the cytoskeleton. Decreased 
expression of E-cadherin is associated with increased invasiveness and metastasis by 
cancer cells (Hanahan and Weinberg 2011). On the other hand, a related protein, N-
cadherin, has been shown to promote invasion and motility in breast cancer cells (Nieman, 
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et al. 1999). The downregulation of E-cadherin and upregulation of N-cadherin in 
carcinomas is often termed the cadherin switch and constitutes part of a broader 
phenomenon known as the epithelial-to-mesenchymal transition, a reference to the 
transformation of non-motile epithelial cells to cancer cells that possess mesenchymal 
cell-like motility and properties (Bacac and Stamenkovic 2007). Other cell membrane 
receptors, known as integrins, primarily associate with glycoproteins in the stromal ECM. 
Integrins act to regulate the migratory ability of cells by controlling adhesion to the ECM 
(Hynes 1992). The expression of integrins in cancer cells is complicated and not well 
understood but does seem to depend on the stage of tumour development (Guo and 
Giancotti 2004). Nonetheless, integrins and related adhesion molecules play an important 
role in the regulation of normal physiological processes in the body and their 
modification is implicated in the development of cancer. 
1.3 Matrix Metalloproteinases 
 Recently, studies investigating cancer metastasis have turned much attention 
towards a group of peptidases known as matrix metalloproteinases or MMPs (Egeblad 
and Werb 2002). In humans, MMPs are a group of at least 23 enzymes, characterized by 
their ability to degrade peptide elements in the ECM (See Table 1.1). They are further 
classified by their substrates into six different families namely, the collagenases, 
gelatinases, stromelysins, membrane-type MMPs, matrilysins and other MMPs (Fink and 
Boratynski 2012). All of these enzymes are similar in that their active sites contain a Zn2+ 
ion, but differ in their location in the cell and substrate specificity. Most MMPs are 
secreted as zymogens, which are non-functional precursors proteins that are activated 
extracellularly. MMPs are naturally inhibited by a group of enzymes known as tissue-
inhibitors of matrix metalloproteinases (TIMPs) (Bauvois 2012). MMPs are among the 
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most recently discovered enzymes, with the first MMP being isolated in 1962 (Gross and 
Lapiere 1962), but are quickly becoming some of the most studied. Despite increased 
research into their function, MMP mechanism of action and function remains poorly 
understood and is highly debated. In addition to causing proteolysis of the ECM, which 
facilitates metastasis and stimulates the release of growth and angiogenic factors, some 
MMPs can also cleave E-cadherin, thereby modifying cellular adhesion properties and 
enhancing cell motility (Moss, Jensen-Taubman and Stetler-Stevenson 2012).  
The discovery of the link between MMPs and ECM destruction and cancer 
metastasis led to a strong interest in MMP activity and many researchers worked to 
develop compounds that could either serve as MMP inhibitors or activators of TIMPs. 
These compounds tended to act on a broad spectrum and included zinc chelators and 
MMP antagonists (Noël, et al. 2012). Examples of such drugs include a variety of 
carboxylic acid, thiole and thioether compounds (Dormán, et al. 2010). Clinical trials for 
these treatments, however, produced disappointing results with some compounds actually 
worsening the patient prognosis (Hidalgo and Eckhardt 2001). Moreover, the adverse side 
effects induced by many of the synthetic MMP inhibitors prevented the administration of 
adequate doses of drug (Coussens, Fingleton and Matrisian 2002). New research suggests 
that the “bulldozer” model, which predicts that all MMPs promote cell migration by 
degrading the surrounding ECM, is flawed. Studies have demonstrated that certain MMPs 
may in fact have tumour suppressing roles during tumorigenesis. The downregulation of 
MMP8, for example, is associated with increased risk of tumour development in mice 
(Balbin, et al. 2003). Likewise, MMP11 inhibits tumour growth while MMP19 reduces 
angiogenesis in tumour cells (Noël, et al. 2012). Noel et al. (2012) called this paradoxical 
relationship among MMPs the “Brake and Booster” model in reference to the stimulatory 
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and inhibitory effects that different MMPs have on cancer metastasis. Although the exact 
mechanisms involved in MMP activity remain under debate, researchers agree that certain 
MMPs play a critical role in ECM remodelling and, therefore, cancer metastasis 
(Balduyck, et al. 2000). These MMPs are overexpressed in cancer cells and compounds 
that are selective in their inhibition of such MMPs are showing promise as possible 
treatments for cancer (Syed, et al. 2004).  
Included in the list of possible MMP targets are gelatinase A and B, also known as 
MMP2 and MMP9, respectively, whose increased expression correlates with increased 
malignancy in breast cancer (Egeblad and Werb 2002). Both MMP2 and MMP9 are 
characterized by their ability to degrade gelatin (John and Tuszynski 2001), which is 
denatured collagen, the most abundant protein in the human body (Di Lullo, et al. 2002) 
and a major polypeptide in the basement membrane of mammary tissue (Monteagudo, et 
al. 1990). Another enzyme of interest is MMP3, which happens to be one of the least 
studied MMPs (Klein and Bischoff 2011). MMP3 is believed to degrade a wide range of 
substrates including fibronectin and laminin (John and Tuszynski 2001). In addition, there 
is evidence that MMP3 may play a role in activating and deactivating other MMPs 
including MMP2 (Klein and Bischoff 2011). All three MMPs are implicated in human 
breast cancer cell angiogenesis and metastasis (Balduyck, et al. 2000; Brasse, et al. 2010; 
Farina, et al. 2011) and thus merit further study. 
1.3.1 Gelatinase A: MMP2 
 MMP2 is one of only two known gelatinases, the other being MMP9. Liotta et al. 
(1979) first discovered MMP2. Pro-MMP2 has a cysteine residue coordinated to the Zn2+ 
ion in the active site (Mecham and Parks 1998). Cleavage of this domain leads to 
activation of MMP2. The activation of pro-MMP2 is of particular interest to researchers 
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as it differs from that of other MMPs. MMP2 associates with TIMP2 and this interaction 
is believed to lead to the transformation of the zymogen into a functional protein. In 
addition to ECM remodelling, MMP2 is believed to be involved in other physiological 
processes including modifying cell adhesion and mitotic activity (Brooks, et al. 1996). 
Regulation of MMP2 is largely achieved by affecting the activation of pro-MMP2, 
specifically by influencing the interaction between MMP2 and TIMP2 (Mecham and 
Parks 1998). Interestingly, studies have shown that the MMP2-TIMP2 complex is 
significantly reduced in breast cancers, indicating that the enzyme may be activated by 
other means in tumour cells (Mecham and Parks 1998).  
 Substrates for MMP2 are not limited to gelatin alone but also include type V, VII, 
X collagens and elastin (Mecham and Parks 1998). Gianelli et al. (1997) showed that the 
degradation of laminin-5 in the basement membrane by MMP2 contributed significantly 
to the enhanced migration of breast cancer cells. Laminin-5 interacts with epithelial cell 
integrins, which facilitates cell adhesion. Disruption of this interaction, therefore, reduces 
cell adhesion and promotes cell motility (Hayashida, et al. 2010). Recent studies also 
show that MMP2 may play a critical role in the processing of various signalling proteins 
(Klein and Bischoff 2011). MMP2 does not appear to possess any tumour-suppressing 
properties unlike some other MMPs. Rather, a high correlation of MMP2 overexpression 
and cancer metastatic potential suggests that MMP2 promotes cancer metastasis (Qin, et 
al. 2008). Many studies have shown that increased MMP2 expression in cells leads to 
increased tumour invasiveness and angiogenic activity (Egeblad and Werb 2002).  
1.3.2 Gelatinase B: MMP9 
 At 92kDa, pro-MMP9 is the largest of all known MMPs and also one of the most 
structurally complex. MMP9 is activated by the proteolysis of a prodomain, in which the 
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Zn2+ active site is bound to a cysteine residue (Van den Steen, Dubois, et al. 2002). This 
is known as the cysteine-switch mechanism, as described by van Wart and Birkedal-
Hansen (1990). The hemopexin-domain in MMP9 is important for regulation by TIMPs 
(Mecham and Parks 1998). MMP9 is most effective at degrading gelatin, although MMP9 
can also cleave collagen type II and collagen type V with some efficiency (Van den Steen, 
Proost, et al. 2002). Interestingly, MMP9 has been shown to affect other proteins not 
found in the ECM, as it can cleave transforming growth factor – β (Yu and Stamenkovic, 
2000) and interleukin (IL)-2 receptor-α (Sheu, et al. 2001) and may also affect the 
activation of MMP3 (Olson, et al. 2000).  
 MMP9 is regulated by changes to gene expression as well as protein secretion, 
activation, glycosylation and the presence of inhibitor proteins (Van den Steen, Dubois, et 
al. 2002). In epithelial cells, transcription of MMP9 is stimulated by several molecules 
including phorbol 12-myristate 13-acetate (PMA) in conjunction with IL-1-α and tumour 
necrosis factor (TNF)-α (Van den Steen, Dubois, et al. 2002). Like most MMPs, MMP9 is 
released as a zymogen and activated extracellularly by TIMP1 and proteinases, like 
trypsin, and even other MMPs including MMP3 (Van den Steen, Dubois, et al. 2002). 
MMP9 is also involved in angiogenesis and can induce the release of VEGF-A, making it 
one of the most researched MMPs by oncologists (Bergers and Benjamin 2002). 
1.3.3 Stromelysin-1: MMP3  
 In the literature, MMP3 appears to be one of the least studied of all MMPs. Active 
MMP3’s molecular weight is 54kDa and it was first discovered in 1974 (Sapolsky, 
Howell and Woessner Jr. 1974). MMP3 is transcribed in the cell as a pre-proenzyme, 
which is then secreted into the extracellular environment as a proenzyme, where it is 
subsequently activated. Like the gelatinases, MMP3 is activated by the cysteine switch 
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mechanism. MMP3 seems to have a broad spectrum of substrates, including different 
types of collagen, fibronectin, laminin, and gelatin (Klein and Bischoff 2011). MMP3 has 
been shown to activate other MMPs such as MMP1, MMP8, MMP9 and MMP13 
(Mecham and Parks 1998). Regulation of MMP3 is generally achieved by influencing 
transcription and translation rather than activation (Mecham and Parks 1998). 
 The role of MMP3 in cancer metastasis has not been clearly established. MMP3 is 
overexpressed in certain cancers such oesophageal carcinomas but is absent in colon and 
gastric carcinomas (Mecham and Parks 1998). MMP3 is upregulated in mammary tissue 
after the lactation period and may induce apoptosis in certain cells (Witty, Wright and 
Matrisian 1995). Some studies also show that MMP3 may influence cell adhesion 
properties by inducing the release of adhesion molecules such as E-cadherin (Noë, et al. 
2001).  
1.4 Piperine: A Dietary Phytochemical 
 Phytochemicals are defined as the bioactive non-nutrient compounds that are 
found naturally in foods from plants (Liu 2003). They include carotenoids, alkaloids, 
phenolics, nitrogen-containing compounds and organosulfur compounds (Liu 2004). The 
clinical benefits of a diet rich in phytochemicals is well documented. Antioxidants in 
apples reduce the incidence of cardiovascular disease, cholesterol levels and lipid 
oxidation (Boyer and Liu 2004). Recently, there has been increased research into 
phytochemicals as possible agents in cancer therapy. Curcumin, found in tumeric, 
possesses chemopreventive properties including cytotoxicity in tumour cells (Teiten, et al. 
2010). Thymoquinone from black caraway seeds reduce breast cancer cell viability 
(Sutton, Doucette and Hoskin 2012). [8]-Gingerol and [6]-gingerol from ginger have 
inhibit murine melanoma tumour progression (Huang, et al. 2013). Phytochemicals are 
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particularly attractive to scientists and clinicians as medications because they tend to be 
well tolerated, have minimal side effects and can be produced at a lower cost when 
compared with other pharmaceuticals (Kadam, et al. 2012). 
One of the more promising phytochemical drugs is piperine, the active ingredient in 
black pepper (Piper nigrum) and long pepper (Piper longum) (See Figure 1.2). Piperine is 
responsible for the pungency associated with black pepper, as it constitutes 5-7% of the 
total mass (Graham 1965). It is classified as an alkaloid and is derived from the amino-
acid, lysine (Koleva, et al. 2012).  The range of physiological benefits of piperine is broad. 
Piperine possesses antioxidant effects, stimulatory effects on pancreatic digestive 
enzymes and the ability to increase digestive capacity (Srinivasan 2007). In addition, 
piperine increases the bioavailabilty of drugs and nutrients in the body (Jin and Han 2010) 
and is effective as an anti-inflammatory drug by inhibiting cyclooxygenase-2 expression 
in murine macrophages (Kim, et al. 2012).  
Piperine potentially possesses some chemotherapeutic properties in different cancers. 
One study demonstrated that piperine caused apoptosis in rectal cancer cells by inducing 
reactive oxygen species (Yaffe, et al. 2013). Piperine has also been reported to suppress 
the development of lung (Selvendiran, Banu and Sakthisekaran 2004) and breast cancers 
(Kakarala, et al. 2010). Piperine inhibits angiogenic activity in human umbilical vein 
endothelial cells (Doucette 2012). Piperine may have potential as a chemotherapeutic 
agent with both anti-angiogenic (Doucette, Hilchie, et al. 2013) and pro-apoptotic activity 
(Lin, et al. 2014). The effects of piperine on the human body do not seem to be 
detrimental to human health (Srinivasan 2007). For the reason that cancer metastasis is 
indicative of more severe disease and poor clinical prognosis, it is important to examine 
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the anti-metastatic properties of piperine in human breast cancer cells and investigate a 
molecular basis of this action.  
1.5. Studying Cancer Metastasis In Vitro 
 While in vivo studies are usually best for establishing concrete conclusions about 
the behaviour of cancer cells in a more complex system, they are often costly and time-
consuming (Welch 1997). In vitro studies are therefore a good first-step in studying the 
effect of a drug on cancer cells as they are not only cost-effective, but also allow for the 
elimination of confounding variables. Many molecular and non-molecular techniques for 
studying cancer cells in vitro have been reported in the literature. A few are described 
here. 
1.5.1 Cell Migration Assays 
 A common method for investigating the metastatic potential of carcinoma cells is 
by observing their migration relative to normal cells (Valster, et al. 2005; Doucette, et al. 
2013). The technique that is often used is a wound-healing assay, whereby a monolayer of 
epithelium is “wounded” by scratching with a pipette tip thus creating an area devoid of 
cells (Peng, et al. 2012; Doucette, et al. 2013). The wound is then observed overtime and 
the rate at which migrating cells fill the void is calculated. By comparing the rates among 
cells under different conditions, one can determine how much more migratory one set of 
cells is as compared to another (Rodriguez, Wu and Guan 2005). The wound-healing 
assay is appealing to scientists because it is simple and inexpensive (Liang, Park and 
Guan 2007). However, because the size of the void created by the pipette tip is dependent 
on the pressure applied, which tends to vary, wound-healing assays tend to yield results 
that are sometimes not reproducible. Furthermore, an added complication arises when the 
void takes longer than 24 h to be filled by migrating cells as the migratory ability of cells 
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becomes confounded with cell proliferation. This problem can be at least partially 
resolved by treating cells with compounds such as mitomycin C that inhibit mitosis 
(Tomasz 1995). 
1.5.2 RT-qPCR 
 Changes in gene expression are particularly important in understanding the 
molecular basis of cancer progression. Many cancer-causing agents act by controlling 
transcription in cells. Drugs that inhibit, stop or reverse these effects may therefore hold 
promise as anti-cancer agents. Real time – quantitative polymerase chain reaction (RT-
qPCR) is a method used to study changes in cellular transcription (Bustin 2000). The 
technique measures the amount mRNA by first isolating mRNA transcripts and then 
using the enzyme, reverse transcriptase, to synthesize complementary strands. The new, 
double-stranded molecules are essentially DNA molecules that mimic the DNA molecule 
from which the mRNA was originally derived. DNA polymerase can then amplify the 
newly synthesized cDNA. In RT-qPCR this amplification is monitored over time. The 
number of cycles taken for a transcript of interest to reach a threshold number is noted. A 
higher number of cycles required is associated with fewer mRNA transcripts present. 
1.5.3 Western Blot 
 Western blotting was first described by Towbin et al. (1979) and is still commonly 
used by scientists to monitor changes in the expression of protein in cells. Various 
proteins, including MMPs, are implicated in several pathways that are associated with the 
development of cancer. The upregulation or downregulation of specific proteins can yield 
valuable information concerning the pathology of certain cancers. Western blots are 
developed by performing sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) on proteins isolated from cells. This technique separates proteins based on 
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their molecular weight. The separated proteins are then transferred to a nitrocellulose 
membrane and probed with antibodies that are specific to the protein of interest. Recently, 
chemiluminiscent reagents have been developed to help quantify isolated proteins (Kurien 
and Scofield 2006). Blots are washed in these reagents and exposed to X-ray film in order 
to visualize protein bands. The intensity of each band corresponds to the quantity of 
protein in that sample.   
1.5.4 Gelatin Zymography 
 When considering the role that the gelatinases play in cancer metastasis, gelatin 
zymography is a powerful technique that can be used to determine gelatinase activity in 
cells (Woo, et al. 2005). In this assay, proteins in tissue culture supernatants are collected 
and separated using SDS-PAGE in a polyacrylamide gel enriched with gelatin. The gel is 
then stained and destained until clear bands where the gelatin has been degraded appear 
against a darkened background. These bands represent gelatinolytic activity and their 
intensity corresponds to the level of activity. Gelatin zymography has been shown to be 
sensitive to not just MMP2 and MMP9, but other MMPs, such as MMP3, which are able 
to degrade gelatin albeit at a lower efficiency (Troth and Fridman 2001).  
1.6 Summary 
 Considering the prevalence and high mortality rates associated with breast cancer, 
there is an urgent need to develop novel, more effective treatments for the disease. 
Perhaps more importantly, these treatments should be cost-effective and well tolerated in 
order to ensure that they are accessible to patients regardless of their socioeconomic 
status. The dietary phytochemical piperine has potential as an anti-cancer treatment. The 
effects of piperine on components breast cancer metastasis therefore merit further 
investigation. 
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1.7 Objectives 
 This study will determine the effect of piperine on cancer cell migration by 
investigating MMP mRNA transcription, MMP protein expression and MMP activation 
in MDA-MB-231 breast cancer cells. This research is also aimed at understanding the 
mechanism of how piperine effects breast cancer cell migration. Piperine has been 
reported to exhibit cytotoxic effects on cancer cells at concentrations of 250 µM and 
higher (Sulina and Kuttan 2004). Therefore, the current study will focus on cell migration 
using piperine at the non-cytotoxic concentrations of 25 µM and 50 µM. The effect of 
piperine at these concentrations will be tested on three different MMPs, namely MMP2, 
MMP9 and MMP3.  
 This research will determine the effect of piperine on the following physiological 
processes. 
1. Cell migration 
2. MMP mRNA expression 
3. MMP protein expression 
4. MMP activation 
It is expected that piperine will inhibit breast cancer migration by inhibiting MMP mRNA 
expression and therefore protein expression and activation. Results from this study will 















Figure 1.1. The Metastatic Cascade. Figure shows some of the key steps involved in 































Table 1.1 MMP families and their substrates. This table lists some MMPs and some of 
their substrates. List was adapted from John and Tuszynski (2001) and Verma and 
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FAMILY MMP SUBSTRATE 
Collagenases MMP1, MMP8, MMP13, 
MMP18 
Fibrillar Collagens 




Matrilysins MMP7, MMP26 Laminin, fibronectin, non-
fibrillar collagens 
Membrane-Type MMPS MMP14, MMP15, MMP16, 
MMP17, MMP24, MMP25 
Gelatinase A 
Gelatinases MMP2, MMP9 Type IV, V and fibrillar 
collagens, gelatin 
Other MMPS MMP12, MMP19, MMP20, 




















Figure 1.2. Piperine is the major alkaloid in black pepper and long pepper. Figure A 
shows the molecular structure of piperine. Figure B shows an image of long pepper, while 
Figure C shows an image of the black pepper plant. Figures B and C were taken from the 
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CHAPTER 2 
MATERIALS & METHODS 
 
 2.1 Materials 
MDA-MB-231 cancer cells were generously provided by Dr. S. Drover of 
Memorial University of Newfoundland. Bovine serum albumin (BSA), bromophenol blue 
solution, Coomassie Brilliant Blue Dye, Dulbecco’s Modified Eagle’s Medium (DMEM), 
dimethyl sulfoxide (DMSO), β-mercaptoethanol, mitomycin C, piperine, 
phenylmethylsulfonyl fluoride (PMSF), phosphate buffered saline (PBS), sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer, and Triton X-100 were 
purchased from Sigma-Aldrich Canada (Oakville, ON, Canada). Dithiothreiotol (DTT), 
deoxyribonucleotide triphosphates (dNTP), fetal bovine serum (FBS), L-glutamine, 
penicillin, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer solution, 
oligo(dT), streptomycin, SuperScript® reverse-transcriptase, trypan blue dye solution, 
TRYPLE™ dissociation reagent, trypsin-EDTA and 5x First-Strand buffer were obtained 
from Invitrogen Canada (Oakville, ON, Canada). Acrylamide/bis-acrylamide, ammonium 
persulfate (APS), sodium dodecyl sulphate (SDS), tetramethylethylenediamine (TEMED), 
tris base and Tween-20 were obtained from Bio-Shop Canada Inc. (Burlington, ON, 
Canada). Anhydrous ethanol was obtained from Commercial Alcohols (Brampton, ON, 
Canada). Ecolite™ scintillation fluid and tritiated thymidine and were purchased from 
MP Biomedicals (Santa Ana, CA, USA). Bio-Rad protein assay dye reagent and gelatin 
powder were obtained from Bio-Rad Laboratories Inc. (Mississauga, ON, Canada). 
Acetic acid and methanol were purchased from Fisher Scientific (Ottawa, ON, Canada). 
Amersham™ ECL™ chemiluminescent reagent was obtained from GE Healthcare Life 
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Sciences (Uppsala, Sweden). Powdered Carnation® skimmed milk was obtained from the 
local grocery store. All RNA primers were obtained from Integrated DNA Technologies 
(Coralville, IA, USA). Rabbit anti-human MMP9 polyclonal and mouse anti-MMP3 
monoclonal primary antibodies were obtained from EMD Millipore (Temecula, CA, 
USA). Rabbit anti-human MMP2 polyclonal primary antibody as well as goat anti-mouse 
IgG- horse-radish peroxidase (HRP), donkey anti-rabbit IgG-HRP and anti-actin (I-9) 
goat polyclonal secondary antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Quantifast SYBR® Green was obtained from Qiagen (Toronto, 
ON, Canada).  
2.2 Maintenance of MDA-MB-231 Cell Line 
MDA-MB-231 cells were cultured in complete Dulbecco’s Modified Eagle 
Medium (cDMEM) made up of 100 U/mL penicillin, 100 µg/mL streptomycin, 10% (v/v) 
heat-inactivated FBS, 2 mM L-glutamine, 5 mM HEPES in DMEM at 37°C under 10% 
humidified CO2. The following procedure was performed for cell subculturing. Cells 
cultured in Corning® (Corning Incorporated Life Sciences, Tewksbury, CA, USA) 75 cm2 
vented flasks were viewed under a Unico® compound light microscope (Unico, Dayton, 
NJ, USA) to confirm adhesion to the bottom of the flask’s inner surface. The cDMEM 
was then carefully pipetted out of the flask and discarded. Trypsin (3 mL) was added to 
the adherent cells and left to stand for approximately 2 min. The sides of the flask were 
tapped to release the adherent cells and complete detachment of the cells confirmed by 
observation under compound light microscope. A volume of 7 mL of cDMEM was then 
added to the detached cells and 2 mL of the cell suspension pipetted into 8 mL of 
cDMEM in a new vented-flask to create a new culture.  Cultures were incubated at 37°C 
under 10% humidified CO2. The subculturing procedure was repeated each time the cells 
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reached approximately 90% confluence as determined by inspection under the 
microscope. As a result, cells were split approximately every 3 days. 
2.3 Cell Migration Assay 
Four sterile, adhesive, Ibidi® two-well culture-inserts (Ibidi, Ingersoll, ON, 
Canada) were placed in Thermo Scientific® 6-well plates at one insert per well. MDA-
MB-231 cancer cells were seeded in each culture-insert well at a concentration of 10,000 
cells per 100 µL cDMEM. The cells were incubated overnight in order to ensure 
sufficient cell adhesion to the plate surface. After the incubation period, cDMEM in each 
culture-insert well was replaced with 100 µL of 10 µg/mL mitomycin C in cDMEM and 
cells were cultured for 2 h. Treatment of cells with mitomycin C was used to inhibit 
proliferation of the cancer cells. Following mitomycin C treatment, cells were allowed to 
recuperate for 12 h.   Piperine solutions of 25 µM and 50 µM were prepared in cDMEM 
from a 150 mM stock solution of piperine in DMSO. The concentration of DMSO in each 
treatment solution was kept constant, including the vehicle control.  Culture-inserts were 
lifted from plates using sterile forceps and a clear void was observed to be separating the 
two cell populations. Cells were washed with 1 mL of cDMEM and treated with 2 mL of 
piperine or its vehicle control. A well with 2 mL cDMEM served as the medium control. 
Images of the void were captured using a Nikon® Digital Sight camera (Nikon Canada Inc, 
Mississisauga, ON, Canada) head connected to a Nikon® Eclipse t5100 microscope 
immediately after treatment, 9 h after treatment and then every 2 h until the void in the 
medium control was observed to have fully closed (33 h). The raw values of the area 
covered by the void at 33 h as determined by Image J software were subtracted from the 
values at 0 h for each treatment. The differences for the vehicle control as well as the 
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piperine treated cells were then divided by the difference for the medium control to obtain 
a value for relative inhibition. 
2.4 Tritiated Thymidine Incorporation Assay 
 A tritiated incorporation thymidine assay was performed to confirm the inhibitory 
effect of mitomycin C on cell proliferation. MDA-MB-231 breast cancer cells were 
seeded into Thermo Scientific® 96-well plates (Fisher Scientific®, Ottawa, ON, Canada) 
at concentrations of 5,000 cells per well in 200 µL cDMEM then incubated overnight.   
After incubation, supernatants were removed and wells were treated with 10 µg/mL 
mitomycin C or its cDMEM control for 2 h after which the mitomycin C solution was 
replaced with 200 µL cDMEM. Twenty millilitres of a 1:1,000 dilution of tritiated 
thymidine in cDMEM was added to each well and then cells were cultured for 6 h. Plates 
were then incubated overnight at -20°C. The following day, the plate was thawed for 20 
min at 37°C and the cells harvested onto filter mats using a Titerek® Cell Harvester 
(Skatron Instruments, Sterling, VA, USA). The mats were placed in scintillation vials and 
1 mL scintillation fluid was added per vial. A Beckman LS6000IC liquid scintillation 
counter (Beckman Coulter Inc., Mississauga, ON, Canada) was used to measure the 
amount of tritiated thymidine incorporated into cellular DNA.  The difference in tritiated 
thymidine incorporation into DNA between samples treated with or without mitomycin C 
was measured 8, 24, 48 and 72 h after initial treatment. The samples were treated with 
tritiated thymidine 6 h before the completion of their respective time-points. All 
scintillation counts were normalized to the 6 h treatment, as this was the reference, and 
each time-point was analyzed for statistical significance using Student’s t-test analysis. 
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2.5 Western Blot Analysis 
2.5.1 Protein Isolation 
 MDA-MB-231 cells were seeded into Corning® 75cm2 canted-neck vented culture 
flasks at 700,000 cells per flask then incubated overnight. Cells were then treated with 
piperine (25 or 50 µM), medium, or vehicle control and cultured for 24 or 48 h. 
Following culture, the media from each flask was pipetted into separate 15 mL centrifuge 
tubes. Adherent cells were harvested using TrypLE, added to its respective media tube  
and centrifuged at 500 x g at 4°C for 5 min. The supernatants were discarded and  pellets 
were resuspended in 1 mL  PBS. The cell suspensions were then transferred into micro-
centrifuge tubes and centrifuged at 500 x g for 5 min at 4°C.  The supernatants were 
discarded, the remaining pellets were lysed in radioimmunoprecipitation assay (RIPA) 
lysis buffer containing 1% Nonyl phenoxypolyethoxylethanol-40 (NP-40), 0.5% sodium 
deoxycholate, 0.1% SDS, 20 mM Tris, 150 mM sodium chloride (NaCl), 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol tetraacetic acid (EGTA) 
at pH 7.5 with 5 µg/mL leupeptin, 5 µg/mL pepstatin, 10 µg/mL apotinin, 100 µM sodium 
orthovanadate, 1 mM DTT, 10 mM NaF, 10 µM phenylaesine oxide and 1 mM PMSF. 
Cells were lysed on ice for 15 min and then centrifuged at 14,000 x g and 4°C for 10 
minutes. Supernatants were then harvested and stored at -80 °C. Protein concentration 
was determined via a Bradford assay. 
2.5.2 Protein Quantification (Bradford Method) & Denaturation 
 One mL diluted (1:4 v/v in ddH2O) Bio-Rad® protein assay dye solution was 
added to 5 µL of each protein supernatant sample. A set of protein standards was 
prepared by mixing increasing volumes of BSA (0, 2.5, 5, 10, 20, 40, 80 µg/mL) with 1 
mL of the dye. Standards and samples were loaded in quadruplicate into Thermo 
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Scientific® 96-well plates at 150 µL per well and analyzed spectrophotmetrically using an 
ASYS Expert 96 microplate reader (Montreal Biotech, Dorval, QC) and DigiRead 
software at a wavelength of 570 nm. The software program, SoftMax® Pro 4.3 LS 
(Molecular Devices, Sunnyvale, CA, USA), was used to calculate sample concentrations 
using a 4-parameter regression on the standard curve. All samples were diluted with the 
appropriate volume of inhibitor cocktail solution to achieve an equal protein 
concentration in each sample for a final volume of 25 µL. In order to denature the protein 
samples, 12.5 µL 3x SDS-sample buffer containing 15% β-mercaptoethanol (v/v), 0.01% 
bromophenol blue (w/v), 30% glyverol (v/v), 6% SDS and 200mM Tris HCl (pH 6.8), 
was added to each sample, mixed and heated at 95°C for 5 min. 
2.5.3 SDS-PAGE Gel Electrophoresis 
 Gel electrophoresis was run on a 12 % acrylamide separating gel containing 
0.15% TEMED (v/v), 0.1 % SDS (w/v), 0.1 % APS (w/v) and 375 mM Tris-HCl (pH 8.8).   
A 4% acrylamide stacking gel was prepared containing 0.3% TEMED (v/v), 0.1% SDS 
(w/v), 0.1% APS (w/v) and 125 mM Tris-HCl (pH 6.8). Protein samples dissolved in SDS 
sample buffer solution were loaded into the wells of the stacking gel at a load rate of 10 
µg of protein per well. A volume of 5 µL of Bio-Rad® protein ladder was loaded into one 
well to serve as a MW reference. Electrophoresis was performed at a voltage of 200 V 
and 120 mA for 60 min in SDS-PAGE running buffer.  
2.5.4 Gel Transfer and Development of Blots 
 Proteins from SDS-PAGE gels were transferred onto a nitrocellulose membrane 
using an iBlot® Gel Transfer Device (Life Technologies™, Burlington, ON, Canada). A 
single gel was placed between an anode and a sheet of filter paper wetted with deionized 
water and a cathode was placed on top of the paper. The sandwiched gel was then placed 
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in the transfer device with a foam sponge inside its lid. The device was run for 7 min. The 
nitrocellulose membrane was trimmed and blocked with 5% (w/v) skim milk in Tween-20 
Tris Buffered Saline (T-TBS) for 60 min with gentle rocking. The skim milk solution was 
then discarded and the membrane was washed  6 times over a 30-min period in T-TBS. 
The blot was then probed with primary antibody overnight at 4°C with gentle shaking. 
The next day, primary antibody was removed and the blot was washed as described above. 
After washing, the blot was placed in secondary antibody for 60 min with gentle rocking 
at room temperature. Secondary antibody was then removed and the blot was washed as 
described above. Primary antibodies against MMP2, actin as well as all secondary 
antibodies were prepared as 1:10000 dilutions in 5% skimmed milk and 1x T-TBS. 
Primary antibodies against MMP3 and MMP9 were prepared as 1:1000 dilutions in 3% 
skimmed milk and T-PBS. Blots were soaked in 2 mL of chemiluminescent reagent and 
developed on Fujifilm® medical x-ray film (Fujifilm, Mississauga, ON, Canada) using a 
Kodak X-OMAT 1000A X-ray developer (Eastman Kodak Company, Rochester, NY, 
USA). Densitometry analysis of the resulting bands was performed using the Image J 
1.47 (National Institutes of Health, Bethesda, MD, USA) software program for Mac OSX. 
2.6 Analysis of mRNA Expression 
2.6.1 RNA Extraction 
 MDA-MB-231 cells were seeded into Corning® 75cm2 canted-neck vented culture 
flasks at 700,000 cells per flask then cultured overnight. The following day, media was 
replaced with medium control, vehicle control, 25 µM and 50 µM piperine treatments and 
cultured for 24 or 48 h. Following culture, RNA was extracted from cells using a Qiagen 
RNeasy® minikit (Qiagen, Toronto, ON, Canada). Centrifugation was performed at 8,000 
x g and 4°C for 15 s. Cells were lifted from culture flasks by replacing their treatment 
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solutions with 3 mL TrypLE™ and then incubating them at 37°C. The solution containing 
lifted cells was centrifuged at 500 x g for 5 min and the supernatant was discarded. Buffer 
RLT (350 µL) and 70% ethanol (350 µL) were added to the cell pellet and mixed 
thoroughly to lyse the cells after which 700 µL was transferred into a 2 mL collection 
tube. The solution was centrifuged in an RNeasy® Mini spin column and the flow-through 
was discarded. Buffer RW1 (350µL) was added to the column and centrifuged and the 
flow-through was discarded. An incubation mix of 50 µL DNase and 350 µL Buffer RDD 
was prepared and centrifuged using a minifuge for 5 s. The incubation mix (80 µL) was 
added to the column membrane and incubated at room temperature for 15 minutes. Buffer 
RW1 (350 µL) was then added to the spin column, centrifuged, and the flow-through was 
discarded. Buffer RPE (500 mL) was added to spin column and centrifuged and flow-
through was discarded. This step was repeated after which the spin column was placed in 
a new 2 mL collection tube and centrifuged for 1 min. The spin column was placed in a 
1.5 mL collection tube and 40 µL of RNase-free water was directly added to the column 
membrane and centrifuged for 1 min. The resulting filtrate, which contained RNA was 
stored at -80°C. Extracted RNA purity was analyzed by loading 1.5 µL onto a Thermo 
Scientific® Nanodrop 2000 spectrophotometer.  
2.6.2 First-Strand cDNA Synthesis 
  RNA (667 ng) from each treatment group was added to RNase-free water in 
microcentrifuge tubes and diluted to a final volume of 10 µL. A volume of 1 µL of 50 µM 
oligo(dT) and 1 µL of 100 mM dNTP was then added to each tube. The mixtures were 
heated to 65°C in a Bio-Rad® T100™ thermal cycler and cooled immediately on ice for 
5-10 min. 4 mL of 5X First-Strand Buffer and 2 µL of 0.1 M dithiothreiotol (DTT) were 
added to each sample, then samples were incubated for 2 min at 42°C. SuperScript® 
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reverse-transcriptase (1 µL) was then added and the reaction mixtures were incubated at 
42°C for 50 min followed by another incubation at 70°C for 15 min. The reaction 
products were stored at -20°C. 
 2.6.3 RT-qPCR  
PCR reaction mixtures contained 5 µL of Qiagen Quantifast SYBR® Green, 1 µL 
of 1 µM sample cDNA, 2 µL RNase-free water and 1 µL each of 1 µM forward and 
reverse primers. The primer sequences are given below. 
• hMMP2 – Forward: 5’-TGG CAA GTA CGG CTT CTG TC-3’; Reverse: 5’-TTC 
TTG TCG CGG TCG TAG TC-3’ 
• hMMP3 – Forward: 5’-GGA GGT TCG TGA AGG-3’; Reverse: 5’-TCC TGG 
CAG AAA TAG GCT TTC-3’ 
• hMMP9 – Forward: 5’-GAA GAG AAA TTC CAT GGA GCC AGG-3’; 
Reverse: 5’-AGA AAT AAA AGA ACC CAA ATT CTT CAA AAA CA-3’ 
• hGAPDH - Forward: 5’-GAG TCA ACG GAT TTG GTC GT-3’; Reverse: 5’-
TTG ATT TTG GAG GGA TCT CG-3’ 
Human glyceraldehyde-3-phosphate dehydrogenase (hGAPDH) served as the loading 
control. The PCR reactions were performed in triplicate using a Corbett Research Rotor 
Gene 6000 series analyzer (Corbett Life Science, Concorde, NSW, Australia). The 
cycling conditions were as follows: 5 min initial heat activation at 95°C, 10 s denaturation 
at 95°C and 30 s extension at 60°C. Forty cycles were used and a melt curve analysis was 
performed. Data was analyzed using the Rotor-Gene 6000 series software program. 
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2.7 Gelatin Zymography Analysis  
2.7.1 Sample Preparation 
 The protocol for the gelatin zymography assay was modified from Toth et al. 
(2012). MDA-MB-231 cells in cDMEM were seeded in Corning® 75cm2 canted-neck 
vented culture flasks at 1,000,000 cells per flask and incubated overnight.  Cells were 
then washed with PBS then treated with medium, vehicle control, or piperine (25 or 50 
µM) for 24 or 48 h in serum-free cDMEM. After the appropriate incubation period, the 
medium from each flask was harvested into separate 15 mL centrifuge tubes and 
centrifuged at 400 x g for 5 min at 4°C. The supernatant was transferred to a 15 mL 
Amicon® centrifugal unit (Billerica, MA, USA) and centrifuged at 14,000 x g for 30 
minutes in order to concentrate the protein. The supernatant (75 µL) was mixed with 25 
µL of 4x sample buffer containing 0.25M Tris/ HCl (pH 6.8), 40% glycerol (v/v), 8% 
SDS (w/v) and 0.01% bromophenol blue (w/v). The mixture was allowed to sit at room 
temperature for 15 minutes. A volume of 75 µL of regular cDMEM (i.e. cDMEM with 
FBS) were also mixed with 25 µL of 4x sample buffer to serve as a positive control.  
2.7.2 Zymography Gel Electrophoresis  
Protein samples were run by electrophoresis on an 8% acrylamide separating gel 
containing 0.1% gelatin (w/v), 0.18% TEMED (v/v), 0.1% SDS (w/v), 0.06% APS (w/v) 
and 300 mM Tris-HCl (pH 8.8). A 4% acrylamide stacking gel was used, containing 0.2% 
TEMED (v/v), 0.1% SDS (w/v), 0.6% APS (w/v) and 65mM Tris-HCl (pH 6.8). Samples 
dissolved in sample buffer were pipetted into gel wells at a load rate of 30 µL protein 
sample per well. Bio-Rad® protein ladder (5 µL) was loaded into one well to use as MW 
reference. Electrophoresis was performed at a voltage of 125 V and 40 mA for 120 min in 
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SDS-PAGE running buffer containing 200 mM glycine, 0.1% SDS (v/v) and 20mM Tris-
HCl (pH 8.3).  
2.7.3. Development of Gel 
Gels were washed for 30 min in 100 mL renaturing solution containing 25% 
Triton X-100 (v/v) in deionized water, with gentle rocking. The renaturing solution was 
then decanted and the gel was rinsed with 300 mL of deionized water. After rinsing, the 
gel was washed with 100 mL 1x developing buffer containing 0.05 M Tris-HCl (pH 7.8), 
0.2 M NaCl, 0.005 M CaCl2 and 0.1% Triton X-100 in deionized water, for 30 min with 
gentle rocking. This buffer solution was then replaced with 100 mL of fresh 1x 
developing buffer solution and incubated at 37°C for 16 h. After incubation, the gel was 
removed from the developing buffer and allowed to sit in staining solution containing 
0.5% Coomassie Blue (w/v), 5% methanol (v/v) and 10% acetic acid (v/v) in deionized 
water, for 60 min until a uniform blue background developed on the gel. Staining solution 
was then decanted and replaced with destaining solution containing 5% methanol (v/v) 
and 10% acetic acid (v/v) in deionized water. The gel was destained until white bands 
appeared, indicating gelatinolytic activity.  
2.8 Statistical Analysis 
All statistical analyses were performed using the GraphPad Prism® 5 software 
program (GraphPad Software, La Jolla, CA, USA) for Mac OSX. The difference in 
proliferation between mitomycin C treated and untreated cells was determined using a 
paired t-test with α=0.05. T-tests were also used to analyze the difference in void widths 
for the cell migration assays. All other statistical analyses were carried out using one-way 
analysis of variance (ANOVA) with a Bonferroni post-hoc test. Differences were said to 
be significant when the p-value was less than 0.05. 




3.1 Mitomycin C Inhibits MDA-MB-231 Breast Cancer Cell Proliferation  
A tritiated thymidine assay was used to determine whether mitomycin C at 10 
ng/mL inhibited MDA-MB-231 breast cancer cell proliferation. It was necessary to 
perform the assay in order to establish that the filling of the void as observed in the cell 
migration assay was due to cell migration alone and not cell proliferation. The tritiated 
thymidine assay showed that cells treated with mitomycin C demonstrated less tritiated 
thymidine incorporation into DNA as compared with mitomycin C untreated cells 
indicating that cell proliferation was indeed inhibited by mitomycin C. It is important to 
note that scintillation counts in the 10 µg/mL mitomycin C treated cells remained fairly 
constant over time while counts in untreated cells increased. This demonstrated that 
tritiated thymidine incorporation remained the same in mitomycin C treated cells. 
Significant differences in tritiated thymidine incorporation were observed for 6, 24, 48 
and 72 h time-points. Graphical representation of these results is given in Figure 3.1. 
3.2 Piperine Inhibits MDA-MB-231 Breast Cancer Cell Migration 
A cell-migration assay was used to determine the effect of non-cytotoxic 
concentrations of piperine on MDA-MB-231 breast cancer cell migration. Treatment of 
the breast cancer cells with 10 µg/mL mitomycin C ensured that cell migration 
calculations were not confounded with cell proliferation. Piperine at a dosage of 50 µM 
significantly reduced MDA-MB-231 breast cancer cell migration into the void created by 
the culture-insert (Figure 3.2). Cells with medium and/or vehicle consistently migrated to 
fill the void created by the culture-insert after 33 h.  
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It was also noted that piperine seemed to change the overall morphology of the 
cells. Piperine-treated cells tended to appear smaller than the untreated cells. The exact 
cause of this change was unknown, however it was not believed to have been a result of 
cell death. Floating cells as a result of a loss in adhesion properties is typically indicative 
of cell death in tissue culture (personal observation). There was no significant number of 
floating cells observed in this experiment. Additionally, patchiness in the cell monolayer 
as a result of detachment was not observed in this experiment, giving further evidence of 
continued viability in the piperine-treated cells.  
3.3 Piperine Inhibits the mRNA Expression of MMP2 and MMP9 but Not MMP3 in 
MDA-MB-231 Breast Cancer Cells  
 For the reason that MMPs play a significant role in cell migration, the possible 
effects of piperine on MMP expression were tested. RT-qPCR showed lower expression 
of MMP2 and MMP9 mRNA in piperine-treated MDA-MB-231 breast cancer cells when 
compared with the vehicle and medium controls. Piperine at 50 µM concentrations 
significantly inhibited MMP2 (Figure 3.3) and MMP9 (Figure 3.5) mRNA expression 
after 48 h of treatment. Significance was determined by one-way analysis of variance 
(ANOVA) with Bonferroni post-hoc test. Piperine treatments after 24 h showed slight 
dose-dependent decreases in MMP2 and MMP9 mRNA expression. Conversely, piperine 
concentrations of 25 and 50 µM at 24 and 48 h time-points had no effect on MMP3 
mRNA expression (Figure 3.4) as determined by one-way ANOVA with Bonferroni post-
hoc test.  
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3.4 Piperine Does Not Decrease MMP2, MMP3 or MMP9 Protein Levels in MDA-
MB-231 Breast Cancer Cells. 
 Analysis by western blot showed no significant inhibition of MMP2, MMP3 or 
MMP9 protein expression by piperine in MDA-MB-231 breast cancer cells.  Distinct 
bands for MMP2 and MMP3 at sizes of 72 kDa and 59 kDa, respectively, were observed 
on the western blots. Blots for MMP9 showed no bands that corresponded to the protein’s 
expected molecular weight (data not shown). Densitometry analysis showed a slight dose-
dependent decrease in MMP2 expression 24 h after treatment with piperine but not after 
48 h (Figure 3.6). As with the RT-qPCR analysis, piperine did not affect MMP3 protein 
expression (Figure 3.7).  
3.5 Analysis of the Effect of Piperine on Gelatinase Activity in MDA-MB-231 Breast 
Cancer Cells Yielded Inconclusive Results. 
Gelatin zymography was used to evaluate the effect of piperine on the activity of 
MMP2 and MMP9 produced by breast cancer cells.  Active MMPs break down gelatin in 
the Coomassie blue-stained gel leading to a clear, unstained band. Unfortunately, 
zymograms were inconclusive in measuring gelatinolytic activity, as they did not produce 
bands that could be measured for the lanes containing sample supernatants. However, 
faint bands corresponding to MMP2 could be seen with the naked eye. These bands 
seemed to show decreased clearance of dye for piperine treated cells compared to vehicle-
treated supernatants, suggesting that piperine could potentially inhibit the conversion of 
pro-MMP2 to active MMP2. No bands were observed that corresponded to the MW of 
MMP9. It is of note that the supernatant from control cultures showed gelatinolytic bands 
corresponding to MMP2 and MMP9. Gelatinases are present in the serum contained in 
cDMEM, thus the gelatinolytic activity by these samples in the zymograms was expected. 
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A representative image of the resulting zymogram is given in Figure 3.8. Better methods 
of concentrating supernatant gelatinases are needed in future experiments in order to 
































Figure 3.1. Mitomycin C inhibits the proliferation of MDA-MB-231 breast cancer cells. 
MDA-MB-231 breast cancer cells treated with 10 µg/mL mitomycin C were tested for 
thymidine incorporation and compared to untreated cells. Scintillation counts were 
normalized to the 6 h time-point. Results are shown for 6, 24, 48 and 72 h after mitomycin C 
treatment in Graphs A, B, C and D respectively. Column graphs show mean counts with 
error bars representing the standard error of the means. A Student’s t-test showed 
significant differences between the mitomycin C treated and untreated cells for each time-










	   38	  
 
 















































































































































































Mitomycin C - +
72 h










Figure 3.2. Piperine inhibits cell migration of MDA-MB-231 breast cancer cells. 
MDA-MB-231 breast cancer cells were treated with piperine or vehicle and observed for 
33 h. Representative images for vehicle and 50 µM piperine treatments are shown at 0 
and 33 h after treatment (A). The void in control cells was consistently observed to be 
filled by migrating cells 33 h after treatment. Graph shows mean width values normalized 
to medium control with error bars representing the standard deviation (B). A Student’s t-
test showed a significant difference between the vehicle control and 50 µM piperine 
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Figure 3.3. Piperine reduces MMP2 mRNA expression in MDA-MB-231 breast cancer 
cells 48 h after treatment. MDA-MB-231 breast cancer cells were treated with vehicle or 
piperine at doses of 25 µM or 50 µM. The mRNA expression for MMP2 was determined by 
RT-qPCR. Cycle threshold (Ct) values were subtracted from GAPDH values to obtain a value 
called the dCt. Each difference was then subtracted from the value for the medium control to 
obtain a ddCt. Fold changes were calculated using the formula y=2-x, where y is the fold 
change value and x is the ddCt.   Column graph shows mean fold change in MMP2 mRNA 
expression with error bars representing the standard error of the mean. Graph A shows the 
results for the 24 h time-point while Graph B shows the results for the 48 h time-point. A 
one-way ANOVA with Bonferroni post-hoc test showed significant inhibition with 50 
µM piperine for the 48 h time-point (p<0.05, n=3). Each experiment was performed in 
triplicate and repeated three times. Significance is shown by (*). 



















































































Figure 3.4. Piperine does not affect MMP3 mRNA expression in MDA-MB-231 breast 
cancer cells. MDA-MB-231 breast cancer cells were treated with vehicle or piperine at doses 
of 25 µM or 50 µM. The mRNA expression for MMP3 was determined by RT-qPCR. Cycle 
threshold (Ct) values were subtracted from GAPDH values to obtain a value called the dCt. 
Each difference was then subtracted from the value for the medium control to obtain a ddCt. 
Fold changes were calculated using the formula y=2-x, where y is the fold change value and x 
is the ddCt.  Column graph shows mean fold change in MMP3 mRNA expression with 
error bars representing the standard error of the mean. Graph A shows the results for the 
24 h time-point while Graph B shows the results for the 48 h time-point. A one-way 
ANOVA with Bonferroni post-hoc test showed no significant differences in treatment 
conditions (p<0.05, n=3). Each experiment was performed in triplicate and repeated three 
times. 
 






















































































Figure 3.5. Piperine reduces MMP9 mRNA expression in MDA-MB-231 breast cancer 
cells after 48 h. MDA-MB-231 breast cancer cells were treated with vehicle or piperine at 
doses of 25 µM or 50 µM. The mRNA expression for MMP3 was determined by RT-qPCR. 
Cycle threshold (Ct) values were subtracted from GAPDH values to obtain a value called the 
dCt. Each difference was then subtracted from the value for the medium control to obtain a 
ddCt. Fold changes were calculated using the formula y=2-x, where y is the fold change value 
and x is the ddCt.   Column graph shows mean fold change in MMP9 mRNA expression 
with error bars representing the standard error of the mean. Graph A shows the results for 
the 24 h time-point while Graph B shows the results for the 48 h time-point. A one-way 
ANOVA with Bonferroni post-hoc test showed significant inhibition at 50 µM for the 48 h 
time-point (p<0.05, n=3). Each experiment was performed in triplicate and repeated three 
times. Significance is shown by (*). 
























































































Figure 3.6. Piperine does not significantly inhibit MMP2 protein expression in MDA-
MB-231 breast cancer cells. MDA-MB-231 breast cancer cells were treated with vehicle or 
piperine at 25 µM or 50 µM. MMP2 protein expression was determined by western blot 
analysis. Figure A shows representative blots for MMP2 with β-actin control bands are 
shown for 24 and 48 h time-points. Western blot protein band densities were normalized to 
β-actin and then compared to the medium control. Column graph shows mean values with 
error bars representing the standard error of the mean. Graph B shows the results for the 24 
h time-point while Graph C shows the results for the 48 h time-point. A one-way 
ANOVA with Bonferroni post-hoc test showed no significant differences in treatment 
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Figure 3.7. Piperine does not decrease MMP3 expression in MDA-MB-231 breast 
cancer cells. MDA-MB-231 breast cancer cells were treated with vehicle or piperine at 25 
µM or 50 µM. MMP3 protein expression was determined by western blot analysis. Figure A 
shows representative blots for MMP3 with β-actin control bands are shown for 24 and 48 
h time-points. Western blot protein band densities were normalized to β-actin and then 
compared to the medium control. Column graph shows mean values with error bars 
representing the standard error of the mean. Graph B shows the results for the 24 h time-
point while Graph C shows the results for the 48 h time-point. A one-way ANOVA with 
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Figure 3.8. Analysis of the effect of piperine on gelatinase activity in MDA-MB-231 
breast cancer cells yielded inconclusive results. Gelatin zymography was used to 
determine the activity of the gelatinases, MMP2 and MMP9, in MDA-MB-231 breast cancer 
cells. Gels were stained with Coomassie-Blue dye and destained with an acetic acid/methanol 
solution. Gelatinase-containing serum medium was used as a positive control. The resulting 
zymogram showed clear bands for the positive control and faint bands for the samples 
corresponding to MMP2. Although piperine treated samples showed reduced clearance, these 
bands were very faint and were not detectable on the photograph. The figure shows a 













































4.1 Effect of Mitomycin C on MDA-MB-231 Breast Cancer Cell Proliferation 
 In this study, it was important to ensure that the proliferation of MDA-MB-231 
breast cancer cells was being inhibited so that the filling of the void by cells in the 
migration assay was due to cell migration alone. The results of the tritiated thymidine 
incorporation assay, which measures the amount of thymidine incorporated into cellular 
DNA, indicated that 10 µg/mL mitomycin C was sufficient to significantly inhibit mitotic 
activity in MDA-MB-231 breast cancer cells (Figure 3.1). Mitomycin C is an antibiotic 
that was first isolated from the bacteria Streptomyces caespitosus (Szybalski and Iyer 
1964). It inhibits mitotic activity in mammalian cells by crosslinking complementary 
strands of DNA (Schwartz, Sternberg and Philips 1963). Specifically, this action of 
mitomycin C prevents cells from proceeding past the S-phase of the cell cycle (Tomasz 
1995). These properties of mitomycin C prompted investigations into its use as a possible 
anti-tumour drug (Mao, Varoglu and Sherman 1999). 
 Mitomycin C is commonly used to treat cells in migration assays. Fronza et al 
(2009) treated 3T3 fibroblasts cells with the 5 µg/mL mitomycin C prior to observing 
their migration in a wound-healing assay. Similarly, Basu et al (2001) used 10 µg/mL 
mitomycin C to inhibit proliferation of dermal fibroblasts. To observe migration of 
keratinocytes, Stojadinovic et al (2005) treated cells with 8 µg/mL mitomycin C. 
Differences in mitomycin C concentrations used to prevent proliferation are likely due to 
different responses to the antibiotic by different cell types.  
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4.2 Effect of Piperine on MDA-MB-231 Breast Cancer Cell Migration 
 Piperine at a concentration of 50 µM significantly inhibited the migration of 
MDA-MB-231 breast cancer cells as demonstrated by the results of the cell migration 
assay (Figure 3.2). In a recent article, 25 and 50 µM piperine were found to inhibit 
migration of SKBR3 breast cancer cells, a cell-line that is characterized by the 
overexpression of HER2 (Do, et al. 2013). The current study, however, investigated the 
effects of 25 and 50 µM piperine on a triple-negative human breast cancer cell-line, which 
lacks the human epidermal growth receptor-2 (HER2), as well as progesterone (PR) and 
estrogen receptors (ER) (Foulkes, Smith and Reis-Filho 2010). Triple-negative breast 
cancers are difficult to treat because they often do not respond to chemotherapy and 
hormone therapy, two of the most common forms of breast cancer treatment (Kawashima, 
et al. 2011). The results of the cell migration assay therefore, not only support the 
findings of Do et al (2013), but also further suggest that piperine may be able to treat 
metastasis in forms of breast cancers that are unresponsive to conventional therapeutic 
methods. 
 While the degradation of ECM is involved in the migration of cells, it is important 
to note that the modification of chemokine signalling and adhesion properties of cells also 
play a role in breast cancer cell migration. Determining the exact physiological process 
that is affected by piperine is beyond the scope of this study but other research indicates 
that piperine may have affected each of these processes to some degree. Kumar, Singhal 
et al. (2007) reported that piperine reduces the expression of intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, 
thereby inhibiting the migratory ability of neutrophils. The same effect was observed in 
human umbilical vein endothelial cells (Kumar, Arya, et al. 2005). Additionally, piperine 
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was shown to modulate cytokine signalling in C57BL/6 murine tumour cells (Sulina and 
Kuttan 2006). The modification of cell adhesion properties as well as chemical 
communication modes may have thus increased the migratory ability of cells in this study. 
 In addition to the degradation of ECM, MMPs are implicated in chemokine 
signalling and the regulation of adhesion molecules in cancer cells. MMP9 stimulates cell 
migration by inducing epidermal growth factor (EGF) in epithelial cells (McCawley, 
O'Brien and Hudson 1998) while MMP2 cleaves C-X-C motif chemokine 12 (CXCL12) 
(Zhang, et al. 2003). CXCL12 is partially responsible for preferential breast cancer 
metastatsis to certain tissues in the body (Müller, et al. 2001). MMP2 also cleaves P-
cadherin, resulting in an increase in the invasive character of cancer cells (Ribeiro, et al. 
2010). MMP2 also modulates cell adhesion by interacting with integrins (Ray and Stetler-
Stevenson 1995). On the other hand, MMP3 is associated with the cleavage of E-cadherin, 
resulting in enhanced cell motility (Lochter, et al. 1997). Piperine may also inhibit cell 
migration by directly influencing processes that affect cell motility such as cytoskeleton 
remodelling (Khajuria, Thusu and Zutshi 2002). The modification of cytoskeleton 
components contributes to breast cancer metastasis (Barkan, et al. 2008). 
 In the current study, it was noted in the cell migration assay that the matrix that 
allowed cells to adhere to the plate surface may not have contained significant amounts of 
collagen and gelatin as would be observed in vivo. This is because fibroblasts and other 
mesenchymal cells are responsible for secreting the collagens and other proteins that 
comprise much of the ECM (Kalluri and Zeisberg 2006). FBS in cDMEM contains 
nutrients and growth factors such as platelet-derived growth factor (PDGF), which is 
implicated in blood clotting (Andrae, Gallini and Betsholtz 2008). Fibroblasts were 
absent in the cell migration assay used in the current study and so did not contribute to 
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matrix formation. Studies by Smith et al. (1979) showed that human epithelial cells in 
culture are capable of producing fibronectin to form an extracellular matrix on which they 
can adhere. Epithelial cells of rat intestines have also showed an ability to synthesize 
fibronectin in culture (Quaroni, Isselbacher and Ruoslahti 1978). Fibronectin may also be 
contained in FBS in appreciable amounts and may be used by cultured cells to form a 
matrix (Hayman and Ruoslahti 1979). These studies suggest then that the migration of 
MDA-MB-231 breast cancer cells in the current study may have occurred via the 
degradation of fibronectin. Fibronectin is a substrate of MMP3, but not MMP2 or MMP9. 
Therefore, while MMP2 and MMP9 may have played significant roles in cell migration 
by regulating cell adhesion and signalling properties, MMP3 and other stromelysins may 
have been the primary source of ECM degradation. Immunocytochemical analysis with 
fluorescent antibodies that are specific to fibronectin would confirm this hypothesis. It 
may be necessary for future studies to monitor cell migration in pre-formed ECM 
containing diverse proteins such as collagens and gelatin. It is also important to note that 
the cell-migration assay observed cell migration in two-dimensions. Future experiments 
may use other analytical methods such as transwell migration assays to determine the 
effect of piperine on cell migration in three-dimensions.  
4.3 Effect of Piperine on MMP2 Expression in MDA-MB-231 Breast Cancer Cells 
 Piperine at concentrations of 50 µM significantly inhibited MMP2 mRNA 
expression in MDA-MB-231 breast cancer cells after 48 h of treatment, as determined by 
RT-qPCR analysis (Figure 3.3). However, this inhibitory effect was lost at the point of 
protein expression as western blot analysis showed no significant inhibition of MMP2 by 
piperine.  Although western blots showed a slight dose-dependent decrease in MMP2 
protein expression after 24 h of piperine treatment, protein levels recovered by 48 h. This 
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was in contrast to RT-qPCR data, which showed that MMP2 mRNA inhibition by 
piperine increased at the 48 h time-point as compared with the 24 h time-point. One 
possible reason for this result is that pro-MMP2 is stored in cells in very minimal 
amounts, with a majority of the protein being secreted upon translation. In this scenario, 
the western blots performed in this study would not have been representative of the actual 
protein expression. Significant differences would thus be expected in the amount of 
secreted MMP2. Sternlicht and Werb (2001) reported that while most MMPs are secreted 
upon translation, some MMPs such as MMP8 and MMP9 are stored in certain immune 
cells. The authors, however, did not comment on MMP2 storage in the cell and it is 
unclear whether the storage of MMPs within the cell is characteristic of immune cells 
only. In future experiments, determining the changes in secreted MMP2 levels may be a 
more accurate method of measuring the effect of piperine on MMP2 protein expression.     
 MMP2 mRNA may also experience post-transcriptional modifications that 
regulate the amount of genetic material that is translated into protein. Post-transcriptional 
modifications are common in cancer cells and often involve the silencing of mRNA 
transcripts (Thomson, et al. 2006). MMP13 mRNA, for example, undergoes significant 
post-transcriptional modifications in tumour cells as compared with normal cells (Yu, et 
al. 2003). A similar mechanism may be involved in MMP2 post-transcriptional regulation 
and may be linked to the threshold quantity of intracellular pro-MMP2 that a cell may 
allow. These modifications may therefore have been reflected in the loss of significant 
MMP2 inhibition as determined by western blot analysis in the current study. 
 Nonetheless, the fact that piperine significantly inhibited MMP2 mRNA levels 
indicated that piperine does influence the regulation of MMP2. This effect of piperine 
may therefore contribute to the inhibition of cell migration as observed in the cell 
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migration assay. Investigations into the effect of piperine on the amount of secreted 
MMP2 and after longer hours of treatment may further clarify the results obtained in this 
study. 
4.4 Effect of Piperine on MMP9 Expression in MDA-MB-231 Breast Cancer Cells 
  Similar to the results for MMP2 mRNA expression, RT-qPCR analysis also 
showed that 50 µM piperine significantly inhibited MMP9 mRNA expression after 48 h 
of treatment. It was to be expected that MMP9 would show a similar response to piperine 
as MMP2, given that both MMPs belong to the same MMP family and there is 
considerable overlap in their substrates (Klein and Bischoff 2011). This result also 
corresponds with a study showing that piperine inhibits mRNA expression of MMP9 in 
4T1 murine breast cancer cells (Lai, et al. 2012). Western blot analysis, however, failed to 
show any bands that corresponded to the MMP9 protein. A likely cause for this result was 
that the primary MMP9 antibody used in the western blot analysis was not sufficiently 
specific or sensitive to detect MMP9. This experiment should be performed again using a 
different antibody to verify this hypothesis. 
 Another possible reason for the discrepancy between MMP9 mRNA and protein 
expression levels is that the MMP9 protein is not expressed in high quantities in cancer 
cells. In similar studies, Lee et al (2007) noted that the basal levels of MMP9 in MCF-7 
human breast cancer cells were negligible and required phorbol 12-myristate 13-acetate 
(PMA) to induce MMP9 expression. PMA was also used to induce MMP9 expression in 
renal carcinoma cells (Hong, et al. 2005). It may therefore be necessary to induce MMP9 
protein expression in future experiments so that the protein can be detected by western 
blot analysis. 
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 As was suggested in the case of MMP2 protein expression, pro-MMP9 may also 
be secreted rapidly after translation. In this case, the results from this study would suggest 
that MMP9 is secreted at a significantly faster rate than MMP2. Jackson and Nguyen 
(1997) reported faster secretion rates of MMP9 relative to MMP2 in human umbilical 
vein endothelial cells. Other investigations suggest that unlike most MMPs, intracellular 
MMP9 may be activated under certain conditions to facilitate quick expulsion from the 
cell (Nguyen, Arkell and Jackson 1998). Activated intracellular MMP9 may not have 
been observed in the current study because the western blot method used was designed to 
detect pro-MMP9 alone. There may be merit, therefore, in testing the effects of piperine 
on secreted MMP9 protein. Using an antibody that can detect both latent and active forms 
of MMP9 may also help to determine if intracellular activation of MMP9 does occur in 
MDA-MB-231 breast cancer cells.  
 Piperine-mediated inhibition of MMP9 mRNA expression may contribute to cell 
migration inhibition observed in 50 µM piperine treated MDA-MB-231 breast cancer 
cells. The effect of piperine on secreted MMP9 should be investigated in order to 
correlate the results between RT-qPCR and western blot analyses. Dose-dependent 
differences in secreted MMP9 protein levels in such an experiment would indicate that 
the inhibitory effect of piperine as observed in mRNA expression also translated to 
protein expression. 
4.5 Effect of Piperine on MMP3 Expression in MDA-MB-231 Breast Cancer Cells 
 The results from the current study showed that piperine affected neither the 
mRNA expression nor the protein expression of MMP3 in MDA-MB-231 breast cancer 
cells (Figures 3.4 and 3.7). Both the data from RT-qPCR and western blot analyses 
showed high variability in mRNA and protein expression values, respectively, as 
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expressed in the large error bars on graphs. Statistical analysis showed that piperine did 
not significantly inhibit MMP3 mRNA expression or protein expression.  
 Selective inhibition of MMPs is preferred in anti-metastatic drugs because non-
specific inhibition of MMPs has yielded poor results in the past (Hidalgo and Eckhardt 
2001). The inability of piperine to significantly inhibit MMP3 expression, despite 
inhibiting the expression of MMP2 and MMP9, therefore demonstrates selectivity in drug 
action. Furthermore, inhibition of MMP3 may be a disadvantage when treating breast 
cancer metastasis because although MMP3 is not very well studied in the literature, at 
least one study shows that MMP3 may induce apoptosis in cells (Si-Tayeb, et al. 2006). 
Another study suggested that MMP3 may inhibit MDA-MB-231 breast cancer 
invasiveness (Farina, et al. 2002). The anti-metastatic role of MMP3 may therefore be 
exploited in the future by drugs that increase intracellular levels of MMP3.  
 MMP3 is also involved in activating and deactivating other MMPs. Ramos-
DeSimone et al (1999) showed that in MDA-MB-231 breast cancer cells, MMP3 
activates and deactivates MMP9, depending on the amount of TIMP1 present. When 
MMP9 is present in lower quantities than TIMP1, MMP3 deactivates MMP9. When 
TIMP1 is present in lower quantities than MMP9, activation of MMP9 occurs. This 
finding offers another reason why the lack of MMP3 inhibition by piperine may be 
beneficial. In the current study, RT-qPCR showed that piperine significantly inhibits the 
mRNA expression of MMP9, which may also result in reduced levels of secreted MMP9. 
Therefore, by keeping MMP9 levels low and leaving MMP3 levels unchanged, piperine 
may be exploiting this convergent pathway of MMP9 activation in inhibiting MDA-MB-
231 breast cancer cell migration. Future studies into the effect of piperine on TIMP1 
levels may determine if piperine decreases MMP9/TIMP1 ratios in breast cancer cells.   
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 Therefore, non-inhibition of MMP3 expression may be an advantage in breast 
cancer treatments because of the pro-apoptotic and anti-migratory roles MMP3 may play 
in a cell. Piperine does not inhibit MMP3 expression in MDA-MB-231 breast cancer cells 
and may thus contribute to cell migration inhibition. Further studies are required to verify 
these results. 
4.6 Effect of Piperine on MMP Activity 
 Gelatin zymography failed to produce any bands corresponding to gelatinase 
activity by MMPs in samples from breast cancer cells (Figure 3.8). Serum-supplemented 
medium, which contains gelatinases, did produce bands of gelatin clearance, indicating 
that the samples did not contain enough active gelatinases to be detected by this method 
of analysis. Faint bands corresponding to MMP2 could be seen on the zymogram with the 
naked eye, however, which confirmed the presence of some active gelatinase in culture 
medium. These bands were too faint to be quantified and thus the results of the gelatin 
zymography were deemed inconclusive. There is some evidence in the literature to 
suggest that piperine inhibits MMP activity in some cancers. For example, Pradeeep and 
Kuttan (2004) reported inhibition of MMP2 and MMP9 activity by piperine in B16F-10 
melanoma cells, as detected by gelatin zymography.  
 One possible reason for the absence of clear bands in gelatin zymography analysis 
was that the concentration of MMP protein in the culture supernatant may have been too 
low to be detected. Even though efforts were made in this study to concentrate 
supernatant proteins, higher concentration of protein may still be needed in order to 
increase the visibility of gelatinase bands. In order to achieve this, cells may be seeded at 
higher concentrations in culture flasks so that more secreted protein will be present in the 
medium. However, if the concentration of seeded cells varied too significantly from the 
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concentration used for the other experiments in this study, i.e. western blot and RT-qPCR, 
the results may not have correlated with the observations made in these other parts of the 
study. More effective spin filters may also be required to further concentrate secreted 
MMPs to make their action more visible on the gelatin zymogram. Lyophilization of the 
culture medium may also help to concentrate the MMPs. 
 Another possible reason for the absence of observable gelatinolytic activity is the 
lack of gelatin and collagen in the matrix of cultured cells. The presence of these proteins 
in the extracellular matrix may be necessary to induce gelatinase activation. Zhuge and 
Xu (2001) have suggested that the presence of type I collagen is implicated in the 
activation of MMP2. Similarly, Bannikov et al (2002) showed that MMP9 binding to 
gelatin or type IV collagen may be necessary to induce enzyme activation. Since the 
quantity of gelatin and collagens in the culture matrix was likely negligible in the current 
study, the gelatinases may not have been activated in appreciable amounts. Future studies 
may therefore require that cells to be sampled for gelatinolytic activity be cultured on a 
coating mixture of gelatin and collagens.  
4.7 Future Directions 
 Given the evidence that MMPs are secreted quickly after translation, it is 
important for future studies to look at the effect of piperine on secreted MMPs. Further 
experiments to investigate the effect of piperine on other MMPs should also be conducted. 
Overexpression of the collagenase MMP13, for example, is known to be associated with 
aggressive forms of breast cancer (Zhang, et al. 2008). It would also be interesting to 
study the effects of piperine on other members of the stromelysin family, such as MMP10, 
to see how they compare with the effects of piperine on MMP3, as determined in current 
study. Other phytochemicals, such as piperlongumine, may also have anti-metastatic 
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properties. Determining if such phytochemicals inhibit cell migration and elucidating a 
mechanism for this action may help scientists better understand the processes involved in 
breast cancer metastasis as it relates to MMP expression. Finally, in vivo studies will help 
to further confirm the results of this study. 
4.8 Conclusions 
 Piperine was found to be a potent inhibitor of MDA-MB-231 human breast cancer 
cell migration. Piperine also inhibited the mRNA expression of the gelatinases, MMP2 
and MMP9. However, piperine did not inhibit the mRNA expression of the stromelysin, 
MMP3. Piperine also did not inhibit the protein expression of MMP2, MMP3 or MMP9. 
It was concluded that analysis of secreted MMPs may offer more accurate information 
about the effect of piperine on MMP protein expression. The effect of piperine on MMP 
activation also did not yield conclusive results. The overall findings in this study, 
however, indicate that piperine inhibits migration of a triple negative breast cancer cell 
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